Cargando…
COVID‐19 pneumonia suspected to be co‐infection with Mycoplasma pneumoniae and improved by early administration of favipiravir and ciclesonide
A female nurse in her 40s caring for a patient with severe coronavirus disease 2019 (COVID‐19) pneumonia treated with a high‐flow nasal cannula (HFNC) presented with fever, cough and dyspnoea. Based on imaging findings and a positive reverse transcription‐polymerase chain reaction (RT‐PCR) for sever...
Autores principales: | Ito, Keima, Yokoyama, Takako, Horiuchi, Minoru, Kato, Munehiro, Usami, Ikuji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8333772/ https://www.ncbi.nlm.nih.gov/pubmed/34377494 http://dx.doi.org/10.1002/rcr2.821 |
Ejemplares similares
-
Antineoplastics/ciclesonide/favipiravir: Pancytopenia and off-label use: case report
Publicado: (2022) -
Therapeutic potential of ciclesonide inhalation for COVID-19 pneumonia: Report of three cases
por: Iwabuchi, Keisuke, et al.
Publicado: (2020) -
Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia
por: Mori, Nobuaki, et al.
Publicado: (2021) -
Ciclesonide/favipiravir/lopinavir/ritonavir: Off-label use, pancytopenia and liver dysfunction: case report
Publicado: (2021) -
Favipiravir, camostat, and ciclesonide combination therapy in patients with moderate COVID-19 pneumonia with/without oxygen therapy: An open-label, single-center phase 3 randomized clinical trial
por: Terada, Jiro, et al.
Publicado: (2022)